Sagimet Biosciences Inc. (SGMT) stock forecast and price target
Price $10.22 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($10.22)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.24 | +21.4% | $0 |
| Next fiscal year ends December 31, 2027 | $-1.45 | −16.7% | $4M |
| Next quarter ends December 31, 2026 | $-0.30 | −3.5% | $0 |
| Quarter after ends March 31, 2027 | $-0.28 | +15.2% | $2M |
Consensus of the analysts covering Sagimet Biosciences, updated daily. In the last 30 days 4 estimates were raised and 0 lowered.
Our model vs. Wall Street
Analysts see 166.9% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Sagimet Biosciences’s intrinsic value about 100% below today’s market value, and it scores 0.4 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Sagimet Biosciences stock price target?
The average 12-month target from 11 analysts is $27.27, 166.9% above the current price of $10.22 Targets range from $7.00 to $50.00.
Is Sagimet Biosciences a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 9 buy, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Sagimet Biosciences expected to earn?
Analysts expect EPS of $-1.24 for the fiscal year ending December 31, 2026 and $-1.45 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.